S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Ayala Pharmaceuticals Earnings Date, Estimates & History

+0.05 (+0.38 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $13.15
50-Day Range
MA: $11.85
52-Week Range
Now: $13.15
Volume34,693 shs
Average Volume28,592 shs
Market Capitalization$168.04 million
P/E RatioN/A
Dividend YieldN/A


Ayala Pharmaceuticals (NASDAQ:AYLA) Earnings Information

Ayala Pharmaceuticals last posted its earnings results on November 17th, 2020. The reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.04. The business earned $0.66 million during the quarter, compared to the consensus estimate of $1.05 million. Ayala Pharmaceuticals has generated $0.00 earnings per share over the last year. Ayala Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 16th, 2021 based off prior year's report dates.

Ayala Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Ayala Pharmaceuticals (NASDAQ:AYLA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-2.36 EPS

Ayala Pharmaceuticals (NASDAQ AYLA) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
11/17/2020Q3($0.5450)($0.59)($0.59)$1.05 million$0.66 millionN/A
8/13/20206/30/2020($0.53)($0.74)($0.74)$0.63 million$1.05 millionN/A
6/22/20203/31/2020($0.64)($1.32)($1.32)$1.00 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.